Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
synthetic pentasaccharide |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AX05
|
| gptkbp:brand |
gptkb:Arixtra
|
| gptkbp:CASNumber |
114870-03-0
|
| gptkbp:contraindication |
severe renal impairment
active major bleeding |
| gptkbp:developedBy |
gptkb:Sanofi
|
| gptkbp:eliminationHalfLife |
17-21 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C31H43N3O49S8
|
| https://www.w3.org/2000/01/rdf-schema#label |
fondaparinux
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
selective inhibition of factor Xa
|
| gptkbp:metabolism |
not metabolized
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:anemia
bleeding thrombocytopenia |
| gptkbp:UNII |
M8G21959BM
|
| gptkbp:usedFor |
treatment of deep vein thrombosis
treatment of pulmonary embolism prevention of deep vein thrombosis |
| gptkbp:bfsParent |
gptkb:Factor_X
gptkb:factor_X |
| gptkbp:bfsLayer |
6
|